Ocrevus continues steady growth trajectory in 2023

The four MS therapies launched since Roche’s therapy have a long way to go to catch up. The fate of late-stage BTK inhibitors remains unclear

February 15, 2024 12:24 AM UTC

Multiple sclerosis market leader Ocrevus brought in over $7 billion in revenue for Roche last year, a 12% increase over 2022. Of the four therapies approved since Ocrevus entered the market in 2017, only one appears to be on a similarly steep growth path.

After an apparent leveling off in sales in the first three quarters of 2023, Roche (SIX:ROG; OTCQX:RHHBY) reported over $1.9 billion in sales of Ocrevus ocrelizumab in the fourth quarter, $206 million more than in 3Q23. With the 4Q bump, the CD20 mAb has managed to maintain a steady growth trajectory since market entry in 2017...